>
Switch to:

Calliditas Therapeutics AB EV-to-EBIT

: -12.11 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Calliditas Therapeutics AB's Enterprise Value is $596.91 Mil. Calliditas Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-49.30 Mil. Therefore, Calliditas Therapeutics AB's EV-to-EBIT for today is -12.11.

NAS:CALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -136.42   Med: -22.75   Max: -10.76
Current: -13.28

-136.42
-10.76

During the past 6 years, the highest EV-to-EBIT of Calliditas Therapeutics AB was -10.76. The lowest was -136.42. And the median was -22.75.

NAS:CALT's EV-to-EBIT is ranked lower than
99.99% of the 626 Companies
in the Drug Manufacturers industry.

( Industry Median: 18.48 vs. NAS:CALT: -13.28 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Calliditas Therapeutics AB's Enterprise Value for the quarter that ended in Dec. 2020 was $725.86 Mil. Calliditas Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-49.30 Mil. Calliditas Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was -6.79%.


Calliditas Therapeutics AB EV-to-EBIT Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBIT Premium Member Only 0.00 0.00 -6.84 -77.90 -15.86

Calliditas Therapeutics AB Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.90 -44.19 -18.84 -14.96 -15.86

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Calliditas Therapeutics AB EV-to-EBIT Distribution

* The bar in red indicates where Calliditas Therapeutics AB's EV-to-EBIT falls into.



Calliditas Therapeutics AB EV-to-EBIT Calculation

Calliditas Therapeutics AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=596.908/-49.296919230681
=-12.11

Calliditas Therapeutics AB's current Enterprise Value is $596.91 Mil.
Calliditas Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -7.3474404949358 (Mar. 2020 ) + -7.1491326996402 (Jun. 2020 ) + -11.844863021433 (Sep. 2020 ) + -22.955483014672 (Dec. 2020 ) = $-49.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (NAS:CALT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Calliditas Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2020 ) =EBIT / Enterprise Value (Q: Dec. 2020 )
=-49.296919230681/725.86486605178
=-6.79 %

Calliditas Therapeutics AB's Enterprise Value for the quarter that ended in Dec. 2020 was $725.86 Mil.
Calliditas Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -7.3474404949358 (Mar. 2020 ) + -7.1491326996402 (Jun. 2020 ) + -11.844863021433 (Sep. 2020 ) + -22.955483014672 (Dec. 2020 ) = $-49.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB EV-to-EBIT Related Terms


Calliditas Therapeutics AB EV-to-EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)